BHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bausch Health Companies Inc (BHC) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown revenue growth and improved debt management, its financial performance is undermined by significant net income losses and declining EPS. Additionally, analysts have mixed views with price targets only slightly above the current price. The technical indicators and options data suggest a neutral to slightly bearish sentiment, and there are no strong proprietary trading signals to support a buy decision.
The MACD is positive but contracting, RSI is neutral at 50.789, and moving averages are converging, indicating no clear trend. Support and resistance levels suggest limited upside potential in the short term, with key resistance at 6.267 and support at 5.641.
Revenue growth for 11 consecutive quarters, with Q4 2025 revenue increasing by 9% YoY.
Improved debt maturity profile through a $1.7 billion debt exchange.
Launch of new products like Clear + Brilliant® Touch laser and ARESTIN®'s 25th anniversary, which could support market share expansion.
Significant net income loss of -$112 million in Q4 2025, down -220.43% YoY.
Declining EPS (-0.3, down -220% YoY).
Analysts express concerns about the loss of exclusivity for key products like Xifaxan by 2027, which could impact future revenue streams.
Phase 3 RED-C program failure, limiting potential market expansion opportunities.
In Q4 2025, revenue increased by 9.26% YoY to $2.796 billion, and gross margin improved to 63.02% (+2.52% YoY). However, net income dropped significantly to -$112 million (-220.43% YoY), and EPS fell to -0.3 (-220% YoY), reflecting poor profitability despite revenue growth.
Analysts have mixed views on BHC. Barclays and Truist maintain neutral or hold ratings with price targets of $7-$8, citing concerns about loss of exclusivity and limited monetization paths. Citi is more optimistic about the broader sector but does not provide a strong buy case for BHC specifically.
